HER2‐negative breast cancers (ER+/PR+/HER2– group) constitute the most prevalent immunopathological subtype, representing more than 66% of all cases, followed by triple negative breast cancers (TNBC), which occur in about 19% of the cases. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.